The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Pirates from across the country attended the funeral of a 14-year-old fan of all things swashbuckling. Billy Maskell, from ...

Sam Slocombe from Devon is campaigning to raise awareness of her daughter Paige's condition, known as Dravet Syndrome. She and her husband Mike said they hoped it would help to improve diagnosis ...

has announced that the U.S. FDA has granted Rare Pediatric Disease Designation for its drug relutrigine in treating Dravet syndrome, a severe genetic epilepsy often linked to SCN1A mutations.

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its ...

Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.

Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial designed to prove that its experimental drug for Dravet syndrome, a severe form of epilepsy, can both reduce ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Stoke Therapeutics (STOK) announced alignment with global regulatory agencies on the design of the company’s Phase 3 EMPEROR study of ...